Renck H, Ljungström K G, Rosberg B, Dhunér K G, Dahl S
Acta Chir Scand. 1983;149(4):349-53.
The incidence of dextran-induced anaphylactoid/anaphylactic reactions (DIAR) was investigated after hapten inhibition employing two different modes of administration of dextran 1 (Mw 1 000 dalton). The trial was carried out as an open prospective study that comprised 12 060 patients. They were randomized into two groups--one receiving a mixture of 20 ml dextran 1, 15%, (Promiten) and 500 ml dextran 70 (Macrodex) or dextran 40 (Rheomacrodex) (admixture group), the other receiving an intravenous injection of 20 ml dextran 1, 15% before the infusion of dextran 70 or 40 (preinjection group). DIAR were graded according to severity from I to V. In the admixture group eight DIAR of grade II, one of grade IV and one of grade V were observed, while in the preinjection group two DIAR of grade II occurred. The admixture of dextran 1 to dextran 70 or 40 does not prevent the occurrence of severe DIAR in the dose investigated.
在采用两种不同给药方式给予葡聚糖1(分子量1000道尔顿)进行半抗原抑制后,研究了葡聚糖诱导的类过敏/过敏反应(DIAR)的发生率。该试验作为一项开放性前瞻性研究进行,共有12060名患者参与。他们被随机分为两组——一组接受20毫升15%的葡聚糖1(Promiten)与500毫升葡聚糖70(Macrodex)或葡聚糖40(Rheomacrodex)的混合物(混合组),另一组在输注葡聚糖70或40之前静脉注射20毫升15%的葡聚糖1(预注射组)。DIAR根据严重程度分为I至V级。在混合组中,观察到8例II级DIAR、1例IV级DIAR和1例V级DIAR,而在预注射组中出现了2例II级DIAR。在所研究的剂量下,将葡聚糖1与葡聚糖70或40混合并不能预防严重DIAR的发生。